Skip to main content

Michael Anthony Moody, MD

Associate Professor of Pediatrics
Associate Professor in the Department of Immunology
Member of the Duke Human Vaccine Institute
Campus mail: 2 Genome Ct, MSRB II Room 3007, Durham, NC 27710
Phone: (919) 668-2551
Email address: tony.moody@duke.edu

Tony Moody, MD is an Associate Professor in the Department of Pediatrics, Division of Infectious Diseases and the Department of Immunology at Duke University Medical Center. Research in the Moody lab is focused on understanding the B cell responses during infection, vaccination, and disease. The lab has become a resource for human phenotyping, flow characterization, staining and analysis at the Duke Human Vaccine Institute (DHVI). The Moody lab is currently funded to study influenza, syphilis, HIV-1, and emerging infectious diseases.

Dr. Moody is the director of the Duke CIVICs Vaccine Center (DCVC) at (DHVI) and co-director of the Centers for Research of Emerging Infectious Disease Coordinating Center (CREID-CC). Dr. Moody is co-PI of a U19 program to develop a syphilis vaccine; this program is led by Dr. Justin Radolf at the University of Connecticut. Dr. Moody is also the director of the DHVI Accessioning Unit, a biorepository that provides support for work occurring at DHVI and with its many collaborators around the world by providing processing, shipping, and inventory support for a wide array of projects.

Dr. Moody and his team are involved in many networks studying vaccine response including the Collaborative Influenza Vaccine Innovation Centers (CIVICs), HIV Vaccine Trials Network (HVTN) and the COVID-19 Prevention Network (CoVPN).

Education and Training

  • Fellowship, Pediatric Infectious Diseases, Pediatrics, Duke University, 2003 - 2006
  • Pediatric Chief Resident, Pediatrics, Emory University, 2002 - 2003
  • Pediatric Internship & Residency, Pediatrics, Emory University, 1999 - 2002
  • M.D., Duke University, 1999

Selected Grants and Awards

Publications

Su, Kuei-Ying, Takuya Nojima, Masayuki Kuraoka, M Anthony Moody, and Garnett Kelsoe. “An in vitro culture system for studying the human B cell repertoire.” In Journal of Immunology, Vol. 190. AMER ASSOC IMMUNOLOGISTS, 2013.

Scholars@Duke

Yang, Guang, T. Holl, Takuya Nojima, Laurent Verkoczy, M. Moody, Barton Haynes, Daisuke Kitamura, and Garnett Kelsoe. “The role of immunological tolerance in humoral responses to the 2F5 epitope of HIV-1.” In Journal of Immunology, Vol. 190. AMER ASSOC IMMUNOLOGISTS, 2013.

Scholars@Duke

Apps, Richard, Ying Qi, Jonathan M. Carlson, Haoyan Chen, Xiaojiang Gao, Rasmi Thomas, Yuko Yuki, et al. “Influence of HLA-C expression level on HIV control.” Science 340, no. 6128 (April 5, 2013): 87–91. https://doi.org/10.1126/science.1232685.

Full Text

Haynes, Barton F., Thomas B. Kepler, Munir Alam, Stephen Harrison, Mattia Bonsignori, M Anthony Moody, Garnett Kelsoe, Laurent Verkoczy, and Hua-Xin Liao. “Analysis of Broad Neutralizing B Cell Lineages to Guide HIV-1 Immunogen Design.” In Jaids Journal of Acquired Immune Deficiency Syndromes, 62:54–54. LIPPINCOTT WILLIAMS & WILKINS, 2013.

Scholars@Duke

Liao, Hua-Xin, Mattia Bonsignori, S Munir Alam, Jason S. McLellan, Georgia D. Tomaras, M Anthony Moody, Daniel M. Kozink, et al. “Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.” Immunity 38, no. 1 (January 24, 2013): 176–86. https://doi.org/10.1016/j.immuni.2012.11.011.

Full Text

Schmidt, Aaron G., Huafeng Xu, Amir R. Khan, Timothy O’Donnell, Surender Khurana, Lisa R. King, Jody Manischewitz, et al. “Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody.” Proc Natl Acad Sci U S A 110, no. 1 (January 2, 2013): 264–69. https://doi.org/10.1073/pnas.1218256109.

Full Text

Bonsignori, Mattia, Justin Pollara, M Anthony Moody, Michael D. Alpert, Xi Chen, Kwan-Ki Hwang, Peter B. Gilbert, et al. “Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.” J Virol 86, no. 21 (November 2012): 11521–32. https://doi.org/10.1128/JVI.01023-12.

Full Text

Bonsignori, Mattia, S Munir Alam, Hua-Xin Liao, Laurent Verkoczy, Georgia D. Tomaras, Barton F. Haynes, and M Anthony Moody. “HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design.” Trends Microbiol 20, no. 11 (November 2012): 532–39. https://doi.org/10.1016/j.tim.2012.08.011.

Full Text

Song, Hongshuo, Jeffrey W. Pavlicek, Fangping Cai, Tanmoy Bhattacharya, Hui Li, Shilpa S. Iyer, Katharine J. Bar, et al. “Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome.” Retrovirology 9 (October 30, 2012): 89. https://doi.org/10.1186/1742-4690-9-89.

Full Text

Moody, M., A. M. Trama, M. Bonsignori, C. Tsao, M. S. Drinker, T. C. Gurley, J. D. Amos, et al. “4 years in a South African subject with broad neutralizing activity.” In Retrovirology, Vol. 9. Springer Science and Business Media LLC, 2012. https://doi.org/10.1186/1742-4690-9-s2-p85.

Full Text

Pages